Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • January 13th, 2020
{MONTH}, {YEAR} (the “Effective Date”) by and between {INSTITUTION NAME; DESCRIBE INSTITUTION}, a [e.g. non-profit, educational, research, healthcare] institution (“Institution”) with an address at
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • January 21st, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of August 31, 2018 (“Effective Date”) by and between University of Miami (“Institution”), having an address at 1320 S. Dixie Highway, Suite 650, Coral Gables, FL 33146, and Cancer Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San Antonio, TX 78208 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • October 11th, 2016
{MONTH}, {YEAR} (the “Effective Date”) by and between {INSTITUTION NAME}, a non-profit, educational, research and healthcare institution (“Institution”) with an address at {INSTITUTION ADDRESS} and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS}(“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • May 15th, 2019
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of this {DAY} day of {MONTH}, {YEAR} (the “Effective Date”) by and between {INSTITUTION NAME}, a non-profit, educational, research and healthcare institution (“Institution”) with an address at {INSTITUTION ADDRESS} and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS}(“Sponsor”). Sponsor and Institution are herein referred to collectively as “Parties.” Individually, each of Sponsor and Institution is a “Party.”
Accelerated Clinical Trial Agreement TemplateAccelerated Clinical Trial Agreement • June 21st, 2022
Lucien has worked on multiple medicines across a variety of therapeutic areas including cardiovascular, neuroscience, nephrology, ophthalmology, dermatology, respiratory and oncology. Division of Cancer Treatment and Diagnosis, NCI, the supplier will be NCI and CTEP will have prepared a Pharmaceutical Data Sheet suitable for copying and pasting into the document as the pharmaceutical section for that agent. Degrees in Microbiology and Clinical Research. Outlines parameters for monitoring and auditing by sponsor and the FDA. Industry Clinical Trials Budgeting and Financial Management. Sponsor has further authorized CRO to bind Sponsor to its obligations within the Accelerated Clinical Trial Agreement for this Study executed between CRO and Institution. Provides verbal and written communication to physician. When done well, sponsors and investigators provide better results not only for the study but also for the patients themselves who seek out and participate in the study. Enabling you
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • September 10th, 2015
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of this day of , 20 (the “Effective Date”) by and between the Regents of the University of Minnesota, a non-profit, educational, research and healthcare university (“University”) with an address at {UNIVERSITY ADDRESS}, and , a corporation having its principal place of business at (“CRO”). CRO and University are herein referred to collectively as “Parties.” Individually, each of CRO and University is a “Party.”
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of September 12,2018 (“Effective Date”) by and between Providence Health & Services - Washington, dba Providence Regional Medical Center Everett (“Institution”), a non-profit corporation organized under the laws of the State of Washington, having an address at 1330 Rockefeller Avenue, Suite 440, Everett, Washington 98201, The Everett Clinic, PLLC, a Washington professional limited liability company with a place of business at 3901 Hoyt Avenue, Everett, WA 98201 (“Clinic”), Jason Lukas, M.D., an employee of Clinic, with a place of business at 1717 13th Street, Suite 300, Everett, Washington 98201 (“Principal Investigator”), and Cancer Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San Antonio, TX 78208 (“CRO”). CRO, Clinic, Principal Investigator, and Institution are herein referred to collectively as “Parties.” Individually, each of CRO, Clinic, Prin
Accelerated Clinical TrialAccelerated Clinical Trial Agreement • August 27th, 2015
CLICK HERE TO ENTER MONTH., CLICK HERE TO ENTER YEAR. (the “Effective Date”) by and between the University of Rochester, a non-profit,
Accelerated Clinical Trial- Agreement -Accelerated Clinical Trial Agreement • May 24th, 2017
This Accelerated Clinical Trial Agreement – Coordinating Center (“Agreement”) is made as of this {DAY} day of {MONTH}, {YEAR} (the “Effective Date”) by and between {INSTITUTION NAME} acting as the coordinating center for the purposes of the study identified below (“Coordinating Center”) a {IDENTIFY INSTITUTION TYPE; e.g., NON-PROFIT, EDUCATIONAL FACILITY} Institution, with an address at {INSTITUTION ADDRESS} and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS} (“CRO”). CRO and Coordinating Center are herein referred to collectively as “Parties” and individually as a “Party.”
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of July 23, 2018 (“Effective Date”) by and between Thomas Jefferson University, a Pennsylvania non-profit corporation (“Institution”), having an address at 125 S. 9th Street, Second Floor Sheridan, Philadelphia, PA 19107, and Cancer Insight, LLC, a limited liability company having its principal place of business at 110 East Houston Street, Floor Seven, San Antonio, TX 78205 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
